Possible scenario
Incremental Scientific Finding
22% Chance
The enzyme class is real but does not materially change near-term gene-editing economics or clinical timelines. Investors treat the headline as an important research advance with modest commercial read-through.
Secondary impacts
- Healthcare -0.2%
Tickers
- PRME-1.2%
- MGX-0.7%
- ILMN+0.3%
- TXG+0.3%
Portfolio impact
S&P 500-0.0%
Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.
Keeping an eye on this scenario?
Tilt can alert you when its probability or impact shifts, or send you a recommendation when it crosses a threshold.